<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667299</url>
  </required_header>
  <id_info>
    <org_study_id>B2020-261</org_study_id>
    <nct_id>NCT04667299</nct_id>
  </id_info>
  <brief_title>Bismuth-Metronidazole Triple Therapy for H. Pylori First-line Treatment</brief_title>
  <official_title>Bismuth-Metronidazole Triple Versus Quadruple Therapy for Helicobacter Pylori First-line Treatment: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled clinical trial will compare the eradication efficacy of&#xD;
      bismuth-metronidazole triple therapy (PPI+bismuth+ metronidazole) with that of&#xD;
      bismuth-metronidazole quadruple therapy (PPI+bismuth+ metronidazole+ amoxicillin) for&#xD;
      Helicobacter pylori first-line treatment. The completion of this trial will expand new&#xD;
      therapy for the treatment of Helicobacter pylori, which can not only ensure clinical&#xD;
      efficacy, but also reduce the use of antibiotics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate of Helicobacter pylori</measure>
    <time_frame>At least 4 weeks after completion of therapy</time_frame>
    <description>Eradication of Helicobacter pylori was defined as negative result of urea breath test (&lt;4‰ cut-off value).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eradication rate of Helicobacter pylori metronidazole-resistant strains</measure>
    <time_frame>At least 4 weeks after completion of therapy</time_frame>
    <description>Eradication of Helicobacter pylori was defined as negative result of urea breath test (&lt;4‰ cut-off value). The strains with minimal inhibitory concentration (MIC) value of metronidazole &gt;8 μg/ml were defined as resistant strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eradication rate of Helicobacter pylori metronidazole-susceptible strains</measure>
    <time_frame>At least 4 weeks after completion of therapy</time_frame>
    <description>Eradication of Helicobacter pylori was defined as negative result of urea breath test (&lt;4‰ cut-off value). The strains with metronidazole MIC value &lt;=8 μg/ml were defined as susceptible strains.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adherence rate</measure>
    <time_frame>At least 1 weeks after completion of therapy</time_frame>
    <description>Adherence was defined as poor when subjects took less than 80% of the total medication.</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>At least 1 weeks after completion of therapy</time_frame>
    <description>Any possible adverse events during the 14-day treatment period were recorded.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>BMT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid and metronidazole 0.4 g qid for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMQ group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and amoxicillin 1 g bid for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole</intervention_name>
    <description>20mg bid</description>
    <arm_group_label>BMQ group</arm_group_label>
    <arm_group_label>BMT group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth potassium citrate</intervention_name>
    <description>0.6g bid</description>
    <arm_group_label>BMQ group</arm_group_label>
    <arm_group_label>BMT group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>0.4g qid</description>
    <arm_group_label>BMQ group</arm_group_label>
    <arm_group_label>BMT group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>1g bid</description>
    <arm_group_label>BMQ group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participate in the trial voluntarily, fully understand the trial, and sign the&#xD;
             informed consent form (ICF).&#xD;
&#xD;
          -  18-75 years old on the day of signing the ICF.&#xD;
&#xD;
          -  Helicobacter pylori infection confirmed by 13C-urea breath test or rapid urease test.&#xD;
&#xD;
          -  Have not received Helicobacter pylori eradication treatment before.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have received Hp eradication treatment.&#xD;
&#xD;
          -  Patients with severe heart, lung, kidney, liver, blood, nerve, endocrine, and&#xD;
             psychiatric diseases.&#xD;
&#xD;
          -  Subjects or guardians refused to participate in the trial.&#xD;
&#xD;
          -  Alcohol and/or drugs Abuse (addiction or dependence) or poor compliance with doctor's&#xD;
             judgment.&#xD;
&#xD;
          -  Have taken antibiotics, bismuth, PPI or Chinese traditional medicine 4 weeks before&#xD;
             treatment.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Active peptic ulcer.&#xD;
&#xD;
          -  allergic to drugs used in the trial.&#xD;
&#xD;
          -  any other circumstances that are not suitable for recruitment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taotao Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qi Chen, MD</last_name>
    <phone>86-17811921405</phone>
    <email>chenqimd@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Chen, MD</last_name>
      <phone>86-18817821405</phone>
      <email>chenqimd@163.com</email>
    </contact>
    <investigator>
      <last_name>Taotao Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qi Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ying Fang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hao Wu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>December 20, 2020</last_update_submitted>
  <last_update_submitted_qc>December 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be available from the principal investigator Taotao Liu at liu.taotao@zs-hospital.sh.cn, beginning 6 months and ending 5 years after the trial results were published. The study protocol and statistical analysis plan are available online from https://clinicaltrials.gov/. All proposals requesting data access will need to specify how it is planned to use the data, and all proposals will need approval of all investigators before data release.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Beginning 6 months and ending 5 years after the trial results were published.</ipd_time_frame>
    <ipd_access_criteria>All proposals requesting data access will need to specify how it is planned to use the data, and all proposals will need approval of all investigators before data release.</ipd_access_criteria>
    <ipd_url>http://clinicaltrials.gov/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

